Great Point Partners’s MoonLake Immunotherapeutics MLTX Stock Holding History

Great Point Partners’s Portfolio MLTX Stock Details MLTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$16.7M	Buy	855,813 +355,813	+71%	+$6.45M	3.15%	13
2026 Q1	$9.32M	Buy	+500,000	New	+$8.28M	2.14%	17
2023 Q2	–	Sell	-278,334	Closed	-$5.95M	–	48
2023 Q1	$5.95M	Sell	278,334 -364,232	-57%	-$6.12M	1.17%	26
2022 Q4	$6.75M	Buy	642,566 +150,566	+31%	+$1.34M	1.32%	27
2022 Q3	$3.82M	Buy	492,000 +60,000	+14%	+$424K	0.92%	28
2022 Q2	$2.27M	Buy	+432,000	New	+$2.72M	0.54%	33

Other funds holding MLTX

BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return

D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

CAM

Cormorant Asset Management Boston, Massachusetts $1.95B AUM 773.9% 1-Year Est. Return

Jupiter Topco New York $245B AUM

LGM

Logos Global Management San Francisco, California $2.32B AUM 536.01% 1-Year Est. Return

WAM

Weiss Asset Management Boston, Massachusetts $9.54B AUM 55.06% 1-Year Est. Return

Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Great Point Partners's MLTX Position: Q2 2026 in Review

Great Point Partners increased its MoonLake Immunotherapeutics (MLTX) stake by 71% in Q2 2026, buying an estimated $6.45M and bringing the position to 855,813 shares worth $16.7M. The position accounts for 3.15% of the portfolio, ranked #13.

Great Point Partners first reported a position in MLTX in Q2 2022 and has held it in 6 quarters since. 173 funds tracked by Wall St. Rank hold MLTX as of Q2 2026.

Great Point Partners held 855,813 shares of MoonLake Immunotherapeutics worth $16.7M as of Q2 2026.
Great Point Partners bought 355,813 MoonLake Immunotherapeutics shares in Q2 2026, an estimated $6.45M.
MoonLake Immunotherapeutics made up 3.15% of Great Point Partners's portfolio in Q2 2026, its #13 holding.
Great Point Partners first reported a position in MoonLake Immunotherapeutics in Q2 2022 and has held it in 6 quarters since.
173 funds tracked by Wall St. Rank held MoonLake Immunotherapeutics as of Q2 2026.

Based on Great Point Partners's 13F filing for Q2 2026, filed 14 Aug 2026.